PARADIGM-HF eligibility in historical German HFrEF populations: clinical characteristics and 1-year outcomes.
BACKGROUND In the PARADIGM-HF trial, sacubitril/valsartan improved outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Because patients enrolled in randomized trials often differ from those in routine care, we assessed the proportion and characteristics of patients fulfilling PARADIGM-HF eli...